T1D Exchange, a nonprofit organization dedicated to advancing type 1 and type 2 diabetes research and care, announced that it will present 13 real-world data studies at the American Diabetes Association's 85th Scientific Sessions, taking place June 20-23, 2025, in Chicago, Illinois. The presentations will showcase research from the organization's Quality Improvement Collaborative (T1DX-QI) and online patient Registry, highlighting emerging trends in diabetes care and outcomes.
Key Research Focus Areas
The studies underscore significant advances in several critical areas of diabetes care, including screening for type 1 diabetes autoantibodies, technology usage with particular emphasis on continuous glucose monitors (CGMs), and the increased use of glucagon-like peptide-1 (GLP-1) therapies by individuals with type 2 diabetes. The research draws on data from the organization's Registry of more than 20,000 people with type 1 diabetes, offering insights into clinical outcomes and the broader impact of the disease, including financial strain, mental health challenges, and comorbid conditions.
"We are excited to unveil impactful research driven by our growing T1DX-QI network and robust patient Registry," said David Walton, Chief Executive Officer of T1D Exchange. "By uniting over 60 endocrinology clinics, data from 150,000+ individuals with T1D and T2D, and patient-reported outcomes from people with T1D and their caregivers, we're building a collaborative, evidence-driven knowledge base to expand our capabilities, deepen datasets, and generate insights that improve care for people with diabetes."
Featured Presentations
A key highlight includes an oral presentation exploring equitable strategies to increase CGM adoption by people with type 2 diabetes, expanding on prior research in type 1 diabetes. This study, designated as "276-OR, T1D Exchange Multicenter Study—Increasing CGM Adoption in Type 2 Diabetes," will be presented on Sunday, June 22, from 3:15 - 4:15 p.m. CT in Room W185 A-D.
Additionally, data from 12 studies will be presented during the General Poster Sessions on Saturday, June 21, Sunday, June 22, and Monday, June 23, from 12:30 - 1:30 p.m. CT in Poster Hall F1.
Registry Impact and Research Platform
"Many of our presentations this year highlight the strength of our engaged T1D community and the value of our growing Registry. Thousands of participants contributed to research that explores the financial, emotional, and clinical realities of living with T1D," said Wendy Wolf, PhD, Vice President of Registry and Outcomes Research at T1D Exchange.
The T1D Exchange Registry serves as both a research database and a recruitment platform for external studies. Wolf noted that the Registry has helped recruit for dozens of research studies, including 16 clinical trials, with more than 10,000 Registry participants enrolled in external studies to date.
Collaborative Network and Data Infrastructure
The T1D Exchange Quality Improvement Collaborative brings together more than 60 endocrinology clinics across the United States, collectively treating over 150,000 people living with type 1 and type 2 diabetes. This network identifies and addresses gaps in care while accelerating evidence-based, practical solutions. Participating clinics contribute anonymized patient data and insights, expanding the collective knowledge base and creating a unified data asset to expedite improvements in care.
The T1D Exchange Registry operates as an online longitudinal study that tracks disease progress and gathers information directly from people with type 1 diabetes and caregivers of children with type 1 diabetes. The Registry includes over 20,000 participants in the United States who share patient-reported outcomes, including data on disease management. Participants update their information annually, participate in internal research projects, and are connected to external curated research opportunities, including clinical trials.
Research Output and Impact
The T1DX-QI and T1D Exchange Registry have contributed to more than 100 publications by T1D Exchange in leading medical journals since 2020, demonstrating the organization's growing influence in diabetes research. The online Registry is specifically designed to lower barriers to participating in diabetes research, including patient populations often underrepresented in clinical studies.
T1D Exchange was established in 2010 as a nonprofit organization with ongoing support from The Leona M. and Harry B. Helmsley Charitable Trust. The organization focuses on harnessing data to advance diabetes care and outcomes through collaborative change, providing clinicians, researchers, industry partners, and advocates with resources and services for better decision support and population health management.
